How Can I Get GLP-1s Covered By Insurance?

By William Gray — The Medicare Dude

GLP-1 medications have quickly become some of the most talked-about prescription drugs in America. Originally developed for type 2 diabetes, these medications have demonstrated significant benefits in weight management, cardiovascular risk reduction, obstructive sleep apnea, chronic kidney disease, and metabolic dysfunction-associated steatohepatitis (MASH).

Unfortunately, obtaining insurance coverage is often far more complicated than obtaining a prescription.

Coverage varies by insurance carrier, employer-sponsored plan, Medicare Part D plan, Medicaid program, diagnosis, and individual medical history.

Understanding how insurers evaluate GLP-1 claims can significantly improve your chances of approval.

Insurance companies generally approve GLP-1 medications when they are prescribed for FDA-approved indications and when patients meet specific medical necessity requirements.

Coverage is typically strongest for:

• Type 2 diabetes
• Chronic weight management
• Obstructive sleep apnea
• Cardiovascular risk reduction
• Chronic kidney disease associated with diabetes
• Metabolic dysfunction-associated steatohepatitis (MASH)

Each insurance company maintains its own coverage criteria and prior authorization requirements.

If you are on Medicare, your Medicare Part D plan formulary determines whether a specific GLP-1 is covered and at what cost-sharing tier. This is one of the most important reasons to compare Part D plans carefully every year — formularies change annually.

Type 2 diabetes remains the most common and most easily approved indication for GLP-1 therapy.

Frequently covered medications include:

• Ozempic
• Mounjaro
• Trulicity
• Rybelsus

Insurance companies commonly require:

• Confirmed diagnosis of type 2 diabetes
• Recent A1C laboratory results
• Documentation of previous treatments
• Compliance with step therapy requirements when applicable

Most plans require prior authorization before approving these medications.

Physicians often must submit:

• Diagnosis codes
• Medical records
• Laboratory results
• Medication history
• Clinical notes demonstrating medical necessity

If you are a Florida Medicare beneficiary managing diabetes, Medicare covers a broad range of diabetes supplies and services — including continuous glucose monitors, insulin, and diabetes self-management training — that work alongside GLP-1 therapy.

Coverage becomes more challenging when GLP-1 medications are prescribed primarily for weight loss.

Most insurers require one of the following:

BMI of 30 or Greater

OR

BMI of 27 or Greater with a Weight-Related Medical Condition

Examples include:

• Hypertension
• Type 2 diabetes
• High cholesterol
• Sleep apnea
• Cardiovascular disease

Many plans also require evidence of:

• Weight history
• Diet and exercise programs
• Nutrition counseling
• Previous weight-loss treatments

Common medications prescribed for chronic weight management include:

• Wegovy
• Zepbound

Even when medical criteria are met, some employer-sponsored plans exclude weight-loss medications entirely.

For a broader look at what Medicare covers for obesity treatment, see our guide on Medicare coverage for weight loss and obesity in 2026.

The FDA's approval of Zepbound for certain patients with obesity and moderate-to-severe obstructive sleep apnea created an additional pathway to coverage.

Supporting documentation often includes:

• Sleep study reports
• Obesity diagnosis
• CPAP history
• Physician documentation supporting treatment necessity

Coverage remains highly dependent upon individual insurance carriers.

Medicare also covers CPAP equipment and related supplies under Medicare Part B durable medical equipment benefits.

GLP-1 medications have demonstrated significant cardiovascular benefits.

Certain patients with obesity, overweight status, and established cardiovascular disease may qualify for coverage when the medication is prescribed to reduce cardiovascular risk.

Insurance companies may request:

• Cardiology records
• Prior cardiac event history
• Weight-related diagnoses
• Current treatment plans

Medicare beneficiaries with heart disease should also review Medicare's coverage for heart disease and cardiovascular conditions.

Some GLP-1 medications have received expanded approval for patients with:

• Type 2 diabetes
• Chronic kidney disease

Coverage may require:

• Kidney function testing
• Diabetes diagnosis confirmation
• Nephrologist records
• Medical necessity documentation

For a complete overview of how Medicare handles kidney disease, see our guide on Medicare and chronic kidney disease in Florida.

Metabolic Dysfunction-Associated Steatohepatitis (MASH) represents another growing area for GLP-1 treatment.

Insurance companies may request:

• Liver specialist documentation
• Fibrosis assessments
• Imaging studies
• Supporting metabolic diagnoses

Coverage policies continue to evolve rapidly.

Before requesting coverage, review your insurance formulary.

Identify:

• Coverage status
• Tier placement
• Prior authorization requirements
• Step therapy requirements
• Quantity limits

Medicare beneficiaries can review their Part D plan formulary at Medicare.gov or by calling their plan directly. This is especially important during the Annual Enrollment Period each fall when you can switch to a plan with better drug coverage.

Determine whether you meet the insurer's written criteria.

Common requirements include:

• Specific diagnoses
• BMI thresholds
• Laboratory evidence
• Previous medication history
• Physician documentation

Most GLP-1 medications require prior authorization.

Your physician's office typically submits:

• Clinical records
• Diagnosis codes
• Laboratory results
• Treatment history
• Medical necessity documentation

Incomplete submissions are among the most common reasons for denial. Medicare Advantage plans have specific prior authorization rules — see our guide on Medicare Advantage prior authorization in Florida for what to expect.

Patients should actively monitor authorization status.

Verify:

• Approval status
• Additional documentation requests
• Effective dates
• Renewal requirements

Many approvals require periodic reauthorization.

Polycystic Ovary Syndrome (PCOS) presents unique coverage challenges because GLP-1 medications are generally not FDA-approved specifically for PCOS treatment.

Coverage is often easier when linked to related diagnoses such as:

• Obesity
• Insulin resistance
• Prediabetes
• Type 2 diabetes
• Metabolic syndrome

Patients improve approval odds when physicians document:

• Weight-related complications
• Metabolic abnormalities
• Previous treatment failures
• Medical necessity

Medicare coverage depends heavily upon why the medication is prescribed.

Traditionally, Medicare Part D has covered GLP-1 medications prescribed for:

• Type 2 diabetes
• Certain cardiovascular indications
• Certain kidney disease indications

Historically, medications prescribed solely for weight loss have faced significant coverage limitations.

However, recent policy developments may change access for some beneficiaries.

If you are approaching Medicare eligibility and concerned about prescription drug costs, this is one of the most important reasons to work with an independent Medicare broker who can compare every Part D plan available in your ZIP code — not just the ones a single carrier offers.

One of the most significant Medicare developments in recent years is the Medicare GLP-1 Bridge Program.

Historically, Medicare beneficiaries seeking GLP-1 medications for obesity treatment often paid hundreds or even thousands of dollars annually out-of-pocket because Medicare generally excluded medications prescribed solely for weight loss.

To address this gap, CMS created the Medicare GLP-1 Bridge Program.

The Medicare GLP-1 Bridge Program is a temporary CMS initiative designed to improve access to certain GLP-1 medications while policymakers continue evaluating broader Medicare obesity-drug coverage options.

CMS has extended the program through December 31, 2027.

The program is expected to begin July 1, 2026.

CMS has announced that eligible beneficiaries may obtain participating GLP-1 medications for approximately:

$50 Per Month

Actual costs may vary based upon:

• Medicare Part D plan participation
• Drug selected
• Pharmacy network
• Eligibility requirements

CMS currently identifies:

• Wegovy
• Zepbound KwikPen
• Foundayo

Additional medications may be added in the future.

Beneficiaries generally must:

• Be enrolled in Medicare Part D
• Meet program eligibility requirements
• Have a valid physician prescription
• Complete prior authorization requirements
• Meet medical necessity standards

Coverage is not automatic.

The Bridge Program primarily addresses obesity-related GLP-1 treatment.

Beneficiaries already eligible for traditional Part D coverage because of:

• Type 2 diabetes
• Cardiovascular indications
• Certain kidney disease indications
• Certain obstructive sleep apnea indications

may receive coverage through standard Part D benefits instead of the Bridge Program.

CMS originally planned broader Medicare participation through the BALANCE Model.

However, the Medicare portion of BALANCE has been suspended indefinitely.

The Medicaid portion of BALANCE continues moving forward through participating states.

Medicaid coverage varies significantly by state.

Common requirements include:

• Prior authorization
• BMI requirements
• Diabetes diagnosis criteria
• Step therapy protocols

Patients should verify coverage directly through their state Medicaid program.

Florida Medicaid beneficiaries who are also eligible for Medicare — known as dual-eligible beneficiaries — may qualify for Extra Help (Low Income Subsidy), which significantly reduces Part D drug costs including GLP-1 medications when covered.

A denial does not necessarily mean coverage is impossible.

Many denials are overturned through appeals.

Review the denial letter carefully.

Common reasons include:

• Missing documentation
• Formulary exclusions
• Failure to meet eligibility requirements
• Step therapy requirements
• Incomplete prior authorization submissions

Work closely with your physician.

Helpful appeal documentation may include:

• Physician letter of medical necessity
• Medical records
• Laboratory results
• Specialist reports
• Weight history
• Prior treatment history

Many approvals occur after appeal. For a complete walkthrough of the Medicare appeals process, see our guide on how to appeal a Medicare denial.

Low-income patients may qualify for manufacturer-sponsored assistance programs.

Eligibility is usually based on:

• Household income
• Insurance status
• Residency requirements

Patients with commercial insurance may qualify for:

• Copay cards
• Savings programs
• Rebates

Government insurance beneficiaries are generally excluded.

Manufacturer programs include:

• NovoCare
• LillyDirect

These programs may provide lower-cost access than traditional retail pharmacies.

Patients should compare pricing among:

• Independent pharmacies
• Mail-order pharmacies
• Discount pharmacy networks
• Cash-pay programs

Medicare beneficiaries should also explore Medicare Extra Help (Low Income Subsidy), which can dramatically reduce out-of-pocket prescription costs for those who qualify.

If GLP-1 coverage remains unavailable, patients should discuss alternatives with their healthcare provider.

Potential options include:

• Metformin
• Contrave
• Qsymia
• Orlistat
• Phentermine
• Other diabetes therapies

Each medication carries unique risks, benefits, and coverage considerations.

GLP-1 medications are transforming the treatment landscape for obesity, diabetes, cardiovascular disease, kidney disease, sleep apnea, and metabolic disorders.

Obtaining insurance coverage often requires persistence, detailed documentation, proper prior authorization, and sometimes multiple appeals.

Patients who understand their plan's formulary, meet eligibility requirements, work closely with their physician, and pursue available financial assistance programs often achieve the best outcomes.

As Medicare, Medicaid, and commercial insurance coverage continue evolving, staying informed remains one of the most valuable tools available to patients seeking access to these medications.

If you are a Florida Medicare beneficiary and want help reviewing your Part D drug plan options or understanding how the Medicare GLP-1 Bridge Program may affect your coverage, William Gray is available for a free consultation. As an independent broker, William compares every plan available in your ZIP code at no cost to you.

"BALANCE Model." Centers for Medicare & Medicaid Services Innovation Center, www.cms.gov/priorities/innovation/innovation-models/balance.

"Coming Soon: CMS to Provide $50 Monthly Access to GLP-1 Medications for Medicare Beneficiaries." Centers for Medicare & Medicaid Services, www.cms.gov/newsroom/press-releases/coming-soon-cms-provide-50-monthly-access-glp-1-medications-medicare-beneficiaries.

"FDA Approves First Medication for Obstructive Sleep Apnea." U.S. Food and Drug Administration, 20 Dec. 2024.

"FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight." U.S. Food and Drug Administration, 8 Mar. 2024.

"FDA Approves New Medication for Chronic Weight Management." U.S. Food and Drug Administration, 8 Nov. 2023.

"FDA Approves Treatment for Serious Liver Disease Known as MASH." U.S. Food and Drug Administration, 14 Mar. 2024.

"Medicare GLP-1 Bridge." Centers for Medicare & Medicaid Services, www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge.

"NovoCare Patient Assistance Program." Novo Nordisk, www.novocare.com.

"Ozempic Approved to Reduce Risk of Worsening Kidney Disease and Cardiovascular Death in Adults with Type 2 Diabetes and Chronic Kidney Disease." Novo Nordisk, 28 Jan. 2025.

"Understanding Medicare Part D Coverage." Medicare.gov, www.medicare.gov.